Osimertinib is a kinase inhibitor indicated for the treatment of patients with a specific type of lung cancer (metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC))1,2,3:

-As first-line treatment of patients whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test1.

-As second line treatment of patients whose disease has progressed on or after EGFR TKI therapy1,2,3.

Osimertinib is used to treat locally advanced or metastatic non-small-cell lung cancer (NSCLC) if the cancer cells are positive for the T790M mutation in the gene coding for EGFR.The T790M mutation may be de novo or acquired following first-line treatment with other tyrosine kinase inhibitors (TKIs) such as Gefitinib and Afatinib.

The standard dosage is: 80 mg orally once daily.

Complete information about Tagrisso (osimertinib) dosage and administration can be found in the official prescribing information listed in our resources section